Soliris Adverse Event Report 2018

$19.99

This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions

Description

Soliris (eculizumab) is a monoclonal antibody. Eculizumab binds to proteins in the blood that can destroy red blood cells in people with genetic conditions that affect the natural defenses of red blood cells. Soliris is used to prevent the breakdown of red blood cells in people with paroxysmal nocturnal hemoglobinuria (PNH). Soliris is also used to treat a rare chronic blood disease called atypical hemolytic uremic syndrome (aHUS) Soliris is also used to treat myasthenia gravis in adults. Soliris is available only under a special program. You must be registered in the program and understand the risks and benefits of this medicine.https://www.drugs.com/soliris.html

Contact US

484-352-2642

What is an Adverse Event Report?

The FDA Adverse Event Reporting System (FAERS) is a database that contains adverse event reports, medication error reports and product quality complaints resulting in adverse events that were submitted to FDA.